UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 39,772 Shares of IQVIA Holdings Inc. (NYSE:IQV)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,226,083 shares of the medical research company's stock after buying an additional 39,772 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.68% of IQVIA worth $290,545,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Versant Capital Management Inc increased its stake in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock valued at $26,000 after buying an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA during the second quarter valued at approximately $27,000. Capital Performance Advisors LLP purchased a new position in shares of IQVIA during the third quarter valued at approximately $27,000. Park Place Capital Corp purchased a new position in shares of IQVIA during the third quarter valued at approximately $28,000. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA during the second quarter valued at approximately $29,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Evercore ISI reduced their price target on IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. The Goldman Sachs Group reduced their price target on IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Truist Financial reduced their price target on IQVIA from $286.00 to $265.00 and set a "buy" rating on the stock in a research note on Monday, November 4th. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research note on Thursday. Finally, BTIG Research reduced their price target on IQVIA from $290.00 to $260.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and a consensus target price of $256.50.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $0.59 during midday trading on Friday, reaching $200.84. 513,717 shares of the company's stock traded hands, compared to its average volume of 1,174,636. The company has a market cap of $36.45 billion, a price-to-earnings ratio of 26.37, a P/E/G ratio of 2.07 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The stock has a 50 day moving average of $218.67 and a 200 day moving average of $226.20.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.